Literature DB >> 25531870

Simultaneous determination of six flavonoids from Paulownia tomentosa flower extract in rat plasma by LC-MS/MS and its application to a pharmacokinetic study.

Bin Dai1, Zhiqiang Hu1, Haiyan Li1, Chong Yan2, Liwei Zhang3.   

Abstract

A simple, rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for simultaneous determination of six components including apigenin, quercetin, apigenin-7-O-β-D-glucoside, quercetin-3-O-β-D-glucoside, 3'-methoxyluteolin-7-O-β-D-glucoside, and tricin-7-O-β-D-glucopyranoside in rat plasma using formononetin as the internal standard (IS). The plasma samples were pretreated by a one-step liquid-liquid extraction with dichloromethane. The chromatographic separation was carried out on a ZORBAX SB-Aq column with a gradient mobile phase consisting of acetonitrile and 2mM aqueous ammonium acetate. All analytes and IS were quantitated through electrospray ionization in negative ion multiple reaction monitoring mode. The mass transitions were as follows: m/z 269.1→117.2 for apigenin, m/z 301.2→151.2 for quercetin, m/z 431.3→311.2 for apigenin-7-O-β-D-glucoside, m/z 463.2→300.2 for quercetin-3-O-β-D-glucoside, m/z 461.3→283.1 for 3'-methoxyluteolin-7-O-β-D-glucoside, m/z 491.3→313.1 for tricin-7-O-β-D-glucopyranoside, and m/z 267.2→252.2 for IS, respectively. All calibration curves exhibited good linearity with correlation coefficient (r)>0.995. The intra-day and inter-day precisions (RSD) at three QC levels were both less than 14.0% and the accuracies ranged from 89.8% to 113.8%. The extraction recoveries of six compounds ranged from 82.3% to 92.5%. The validated method was successfully applied to pharmacokinetic study of the six components in male rat plasma after oral administration of Paulownia tomentosa flower extract.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Flavonoids; LC–MS/MS; Paulownia tomentosa; Pharmacokinetic study

Mesh:

Substances:

Year:  2014        PMID: 25531870      PMCID: PMC7105214          DOI: 10.1016/j.jchromb.2014.11.021

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


Introduction

Paulownia tomentosa Steud. is an important member of the Scrophulariaceae family that is widely used in traditional medicine for the treatment of infectious diseases, such as gonorrhea and erysipelas [1], [2], [3]. It has a wide spectrum of bioactivities, including neuroprotective, antioxidant, antibacterial, antiphlogistic, antiviral, and cytotoxic activities [4], [5], [6], [7], [8], [9]. Therefore, determining the concentration of active components in P. tomentosa in biological samples for pharmacokinetic study is significant. Flavonoids, lignans and iridoids are bioactive compounds of P. tomentosa [10], [11], [12]. Among these compounds, flavonoids are known because of their main bioactive constituents [13], [14], [15]. The flavonoids from P. tomentosa exhibited significant neuroprotective activity against glutamate-induced toxicity, and showed potent inhibition of human acetylcholinestrase and butyrylcholinestrase, which are linked to the amelioration of Alzheimer's symptoms [16], [10], [4]. Moreover, the flavonoids of P. tomentosa displayed the inhibition of SARS-CoV papain-like protease that is an important antiviral target due to its key roles in SARS virus replication [6]. Several reports [17], [18], [19] have indicated that flavonoids, such as apigenin, quercetin, apigenin-7-O-β-d-glucoside, quercetin-3-O-β-d-glucoside, 3′-methoxyluteolin-7-O-β-d-glucoside, and tricin-7-O-β-d-glucopyranoside had played an important role in P. tomentosa or P. fortunei. Investigating the pharmacokinetics of these flavonoid components is necessary to better use P. tomentosa. Accordingly, a simple, sensitive, and robust liquid chromatography–tandem mass spectrometry (LC–MS/MS) is required to determine the flavonoids in the biological matrix. In this study, we developed a simple LC–MS/MS method for the simultaneous determination of six flavonoids (apigenin, quercetin, apigenin-7-O-β-d-glucoside, quercetin-3-O-β-d-glucoside, 3′-methoxyluteolin-7-O-β-d-glucoside, and tricin-7-O-β-d-glucopyranoside) in rat plasma and their pharmacokinetics after oral administration of P. tomentosa flower extract.

Experimental

Materials and reagents

Standards of apigenin, quercetin, apigenin-7-O-β-d-glucoside, quercetin-3-O-β-d-glucoside, 3′-methoxyluteolin-7-O-β-d-glucoside, tricin-7-O-β-d-glucopyranoside, and formononetin (used as internal standard) were purchased from the CRM/RM Information Center of China (Beijing, China) (Fig. 1 ). HPLC-grade acetonitrile and methanol were purchased from Merck (Darmstadt, Germany). HPLC-grade water was obtained from a Milli-Q Water Purified System (Millipore, Bedford, MA, USA). Other reagents were of analytical grade.
Fig. 1

The chemical structures of six flavonoids.

The chemical structures of six flavonoids.

Chromatographic conditions

The HPLC system consisted of an Agilent 1200 series (Agilent Technologies, Wilmington, DE, USA). Samples were separated on a ZORBAX SB-Aq (5 μm; 150 mm × 4.6 mm) column with a Security-Guard C18 (5 μm; 4.6 mm × 3 mm) column. A linear gradient elution of eluents A (2 mM aqueous ammonium acetate) and B (acetonitrile) was used for the separation, using a B gradient elution of 30% at 0–1 min, 30–70% at 2–5.5 min, and the reequilibration time of gradient elution was 5 min. The flow rate was set at 0.9 mL/min with split ratio of 2:1 (v/v), and the total run time was 10.5 min.

Mass spectrometric conditions

Ionization and detection of the six flavonoids and IS were carried out on an Agilent 6460 triple–quadrupole mass spectrometer (Agilent Technologies, Palo Alto, CA, USA) equipped with electrospray ionization (ESI) source and operating in negative ion mode. Data acquisition and quantification were performed by Agilent MassHunter workstation B.03.01 software (Agilent Technologies, USA). The drying gas temperature was maintained at 300 °C; the heater temperature was set at 350 °C at a sheath gas flow of 11 L/min; and the nebulizing gas (N2) pressure and capillary voltage were set at 45 psi and −4.0 kV. The dwell time was 50 ms for each compound, and mass analyzers Q1 and Q3 operated at unit mass resolution were used for each multiple reaction monitoring (MRM) transition. Compound-dependent parameters are listed in Table 1 .
Table 1

Summary of the retention times, MS/MS parameters, and precursor and product ions observed for each compound.

CompoundRetention time (min)Precursor ion (m/z)Product ion (m/z)Optimal collision energy (eV)Optimal fragmentor voltage (V)
Apigenin4.43269.1117.225100
Quercetin4.21301.2151.228100
Apigenin-7-O-β-d-glucoside2.80431.3311.211130
Quercetin-3-O-β-d-glucoside2.94463.2300.225145
3′-Methoxyluteolin-7-O-β-d-glucoside3.22461.3283.130120
Tricin-7-O-β-d-glucopyranoside3.35491.3313.125135
IS4.71267.2252.22590
Summary of the retention times, MS/MS parameters, and precursor and product ions observed for each compound.

Preparation of P. tomentosa flower extract

Flowers were collected in Anhui, China, in April 2013, and identified by one of us (Prof. Chong Yan) as P. tomentosa flowers. A voucher specimen (No. 201304YC) was deposited in the Chinese medicine specimens room, Guangdong Medical College (Dongguan, China). P. tomentosa flower extract (20 g) was soaked twice for 1 h in 70% ethanol (400 mL) at 80 °C [20], [21]. The extracted solution obtained by filtration was concentrated under reduced pressure and used as samples for animal studies. To calculate the administered dose, we quantitatively determined the contents of the six constituents in the P. tomentosa extract through an external standard method using the same chromatography conditions previously described. The results showed that the concentrations of apigenin, quercetin, apigenin-7-O-β-d-glucoside, quercetin-3-O-β-d-glucoside, 3′-methoxyluteolin-7-O-β-d-glucoside, and tricin-7-O-β-d-glucopyranoside in the extract were 0.063, 0.101, 0.033, 0.048, 0.231, and 0.167 mg/mL, respectively.

Preparation of standard and quality control (QC) samples

Mixed stock solutions containing above six standards were prepared in methanol with a final concentration of 0.513 mg/mL for apigenin, 0.421 mg/mL for quercetin, 0.381 mg/mL for apigenin-7-O-β-d-glucoside, 0.320 mg/mL for quercetin-3-O-β-d-glucoside, 0.513 mg/mL for 3′-methoxyluteolin-7-O-β-d-glucoside, and 0.602 mg/mL for tricin-7-O-β-d-glucopyranoside, respectively. The mixture stock solution was serially diluted with a mixture of methanolwater (50:50, v/v) to provide working standard solutions of desired concentrations. The IS stock solution of 1.00 mg/mL was prepared in methanol. The IS working solution (100 ng/mL) was prepared by diluting the stock solution with methanolwater (50:50, v/v). Plasma samples of standard calibration curves were prepared by spiking 10 μL of the above working solutions into 190 μL of blank plasma. The plasma concentrations were in the range of 5.13–513 ng/mL for apigenin, 4.21–421 ng/mL for quercetin, 3.81–381 ng/mL for apigenin-7-O-β-d-glucoside, 3.20–320 ng/mL for quercetin-3-O-β-d-glucoside, 5.13–513 ng/mL for 3′-methoxyluteolin-7-O-β-d-glucoside, 6.02–602 ng/mL for tricin-7-O-β-d-glucopyranoside, respectively. QC samples at low, middle and high concentrations (10.26, 61.56, 461.7 ng/mL for apigenin; 8.42, 50.52, 378.9 ng/mL for quercetin; 7.62, 45.72, 342.9 ng/mL for apigenin-7-O-β-d-glucoside; 6.40, 38.4, 288 ng/mL for quercetin-3-O-β-d-glucoside; 10.26, 61.56, 461.7 ng/mL for 3′-methoxyluteolin-7-O-β-d-glucoside; 12.04, 72.24, 541.8 ng/mL for tricin-7-O-β-d-glucopyranoside) were also prepared by the same operation listed above. All the solutions were kept at 4 °C.

Sample preparation

A simple liquid–liquid extraction (LLE) method was applied to extract the six flavonoids and IS from rat plasma. To a 50 μL of the rat plasma, 25 μL of IS and 25 μL of 0.1 M hydrochloric acid were added. The mixture was vortexed for 1 min and extracted with 1 mL of dichloromethane by shaking on a vortex mixer for 5 min. The upper layer was transferred to a clean tube after centrifugation at 5000 ×  g for 5 min and then evaporated to dryness under a gentle stream of nitrogen. The obtained residue was reconstituted in 50 μL of mobile phase and centrifuged at 11,000 ×  g for 5 min. Subsequently, aliquots of 10 μL were injected into the LC–MS/MS system for analysis.

Method validation

The method was validated according to the principles of the FDA industry guidance [22], [23].

Selectivity

To ensure whether other endogenous components from plasma interfered with the analytes, samples from six different blank rats were analyzed.

Calibration curves and sensitivity

The linearity of each calibration curve was determined by plotting the peak area ratios of analyte:IS vs apigenin, quercetin, apigenin-7-O-β-d-glucoside, quercetin-3-O-β-d-glucoside, 3′-methoxyluteolin-7-O-β-d-glucoside, and tricin-7-O-β-d-glucopyranoside concentrations in rat plasma. The linearity of the calibration curve was determined by linear regression analysis and the acceptable value for correlation coefficient (r) was ≥0.995. Method sensitivity was determined by lower limit of detection (LLOD) and lower limit of quantification (LLOQ) based on a signal-to-noise (S/N) ratio of 3:1 and 5:1, respectively.

Precision and accuracy

Precision and accuracy were investigated by analyzing six replicates of QC samples on the same day (intra-day) and between three different days (inter-day). The intra-day and inter-day precisions were expressed by the relative standard deviation (RSD), and the accuracy was evaluated by expressing the mean calculated concentration as a percentage of the spiked concentration. Acceptance criteria met that accuracy should be less than ±15% and precision be below 15%.

Matrix effect and recovery

The matrix effect of the six analytes and IS was evaluated by analyzing triplicates of plasma samples at three QC levels. Matrix effect was evaluated by comparing corresponding peak areas of plasma extracts spiked with analytes with those of standard solutions. The extraction efficiency was also investigated by determining triplicates of plasma samples. The extraction recovery was analyzed by comparing the peak areas of plasma extracts spiked with analytes before extraction with those of the post-extraction spiked samples.

Stability

Stability of six analytes in rat plasma was determined by analyzing triplicates of QC samples during the sample processing and storage stage. Samples were stored at ambient temperature for 6 h and at −20 °C for 3 weeks to assess short-term and long-term stability, respectively. Freeze–thaw stability was determined after three freeze–thaw cycles between −20 °C and ambient temperature.

Pharmacokinetic study

Six male Wistar rats (weighing 220 ± 20 g) were housed under constant temperature (20 ± 2 °C), humidity (50 ± 15%) and lighting (12 h light per day) and were deprived of food for 12 h with water ad libitum before the experiment. The experimental protocols were approved by the Animal Care and Use Committee of Guangdong Medical College (Dongguan, China). Six rats received an intragastric administration of 183 mg/kg P. tomentosa flower extract solution (equivalent to 0.63 mg/kg of apigenin, 1.01 mg/kg of quercetin, 0.33 mg/kg of apigenin-7-O-β-d-glucoside, 0.48 mg/kg of quercetin-3-O-β-d-glucoside, 2.31 mg/kg of 3′-methoxyluteolin-7-O-β-d-glucoside, and 1.67 mg/kg of tricin-7-O-β-d-glucopyranoside). Blood samples (about 250 μL) were collected in heparinized tubes via the jugular veins from each rat at 0, 5, 10, 25, 40 min, and 1, 2, 3, 4, 6, 8, 12 and 24 h after administration, and were immediately centrifuged at 5000 ×  g for 5 min to collect plasma. The obtained plasma samples were stored at −20 °C until analysis. To determine the main pharmacokinetic parameters of the six analytes, the pivotal pharmacokinetic parameters were calculated by the non-compartmental analysis using DAS 2.1 software package (Chinese Pharmacological Society, China).

Results and discussion

Optimization of LC–MS/MS conditions

Individual analyte solutions were directly infused into the mass spectrometer under the positive and negative ion scan mode. Under the selected ESI condition, all six analytes and IS showed higher sensitivity in the negative mode than in the positive mode, and the most abundant ions are [M−H]− for all analytes. Therefore, the deprotonated form of each compound, the [M−H]− ion, was the parent ion in the Q1 spectra and used as the precursor ion to obtain Q3 product ion spectra. The MS/MS product ion spectra of the analytes and IS are shown in Fig. 2 . On the basis of that, to get the maximum response of precursor and product ions, the parameters for fragmentor voltage and collision energy were further optimized. Table 1 shows the optimal fragmentor voltage and collision energy of all the analytes. Finally, the most sensitive mass transition was monitored from m/z 269.1 to 117.2 for apigenin, m/z 301.2 to 151.2 for quercetin, m/z 431.3 to 311.2 for apigenin-7-O-β-d-glucoside, m/z 463.2 to 300.2 for quercetin-3-O-β-d-glucoside, m/z 461.3 to 283.1 for 3′-methoxyluteolin-7-O-β-d-glucoside, m/z 491.3 to 313.1 for tricin-7-O-β-d-glucopyranoside, and m/z 267.2 to 252.2 for IS.
Fig. 2

The product ion fragmentation modes and mass spectra of six flavonoids and IS (a, apigenin; b, quercetin; c, apigenin-7-O-β-d-glucoside; d, quercetin-3-O-β-d-glucoside; e, 3′-methoxyluteolin-7-O-β-d-glucoside; f, tricin-7-O-β-d-glucopyranoside; g, IS).

The product ion fragmentation modes and mass spectra of six flavonoids and IS (a, apigenin; b, quercetin; c, apigenin-7-O-β-d-glucoside; d, quercetin-3-O-β-d-glucoside; e, 3′-methoxyluteolin-7-O-β-d-glucoside; f, tricin-7-O-β-d-glucopyranoside; g, IS). The peak symmetry of the analytes greatly improved after adding ammonium acetate to the mobile phase. Thus, the concentration of ammonium acetate in aqueous phase was optimized from 1 to 10 mM, and the results showed that adding 2 mM ammonium acetate produced good improvement. In addition, a gradient elution program was used to reduce the retention time and eliminate excessive broadening of the chromatographic peaks. Finally, the optimized gradient elution mentioned in Section 2.2 was adopted. Selectivity was evaluated by extracting blank plasma from six different sources and comparing the MS/MS responses at the retention times of six analytes to those of the LLOQ level (Fig. 3 ). No significant peaks were observed in any lane of the blank plasma samples for the six analytes and IS.
Fig. 3

Representative MRM chromatograms of six flavonoids and IS in plasma. (a) Blank plasma; (b) blank plasma spiked with IS; (c) blank plasma spiked with six analytes at LLOQ and IS; (d) 2.0 h plasma sample after oral administration of P. tomentosa flower extract.

Representative MRM chromatograms of six flavonoids and IS in plasma. (a) Blank plasma; (b) blank plasma spiked with IS; (c) blank plasma spiked with six analytes at LLOQ and IS; (d) 2.0 h plasma sample after oral administration of P. tomentosa flower extract.

Linearity and sensitivity

The calibration curves, correlation coefficients and linear ranges of six analytes in plasma are listed in Table 2 . The regression equation of the calibration curve was expressed as Y  =  kX  +  b, Y is the peak area ratio of the analyte to IS and X is the corresponding concentration value. All the calibration curves showed good linearity in their corresponding ranges for the six analytes (r  > 0.995).
Table 2

Regression data and LLOQs of six analytes in plasma.

CompoundRange (ng/mL)Linear regression equationCorrelation coefficientLLOQ (ng/mL)
Apigenin5.13–513Y = 0.0021X + 0.00620.99625.13
Quercetin4.21–421Y = 0.0017X + 0.00330.99514.21
Apigenin-7-O-β-d-glucoside3.81–381Y = 0.012X + 0.06950.99873.81
Quercetin-3-O-β-d-glucoside3.20–320Y = 0.035X + 0.10210.99963.20
3′-Methoxyluteolin-7-O-β-d-glucoside5.13–513Y = 0.052X + 0.23100.99515.13
Tricin-7-O-β-d-glucopyranoside6.02–602Y = 0.068X + 0.87450.99536.02
Regression data and LLOQs of six analytes in plasma. The LLOD and LLOQ obtained using the calculation of the S/N ratio were found to be 3.08 and 5.13 ng/mL for apigenin, 2.53 and 4.21 ng/mL for quercetin, 2.29 and 3.81 ng/mL for apigenin-7-O-β-d-glucoside, 1.92 and 3.20 ng/mL for quercetin-3-O-β-d-glucoside, 3.08 and 5.13 ng/mL for 3′-methoxyluteolin-7-O-β-d-glucoside, 3.61 and 6.02 ng/mL for tricin-7-O-β-d-glucopyranoside in plasma. The limits were sufficient for pharmacokinetics studies. The intra-day and inter-day precisions and accuracy are presented in Table 3 . The RSD values for intra-day and inter-day precisions were all within 14.0%, whilst the accuracy values were all below 113.8% at each QC level. The results suggested that the present assay showed acceptable accuracy and precision.
Table 3

Intra-day, inter-day precision and accuracy of six analytes in plasma (n = 6).

CompoundConcentration (ng/mL)Intra-day
Inter-day
Precision (RSD, %)Accuracy (%)Precision (RSD, %)Accuracy (%)
Apigenin10.262.3107.84.796.2
61.5611.795.68.6101.3
461.76.298.76.3102.7
Quercetin8.420.798.22.292.5
50.522.7113.83.9105.6
378.98.1104.24.398.9
Apigenin-7-O-β-d-glucoside7.627.497.311.1107.8
45.7214.092.89.695.6
342.95.289.82.096.4
Quercetin-3-O-β-d-glucoside6.401.0104.45.798.1
38.44.294.08.399.6
2889.791.66.193.4
3′-Methoxyluteolin-7-O-β-d-glucoside10.265.7100.04.5105.5
61.5610.0103.613.897.1
461.77.897.29.6111.9
Tricin-7-O-β-d-glucopyranoside12.043.8113.76.298.2
72.243.395.61.796.3
541.86.2101.14.398.2
Intra-day, inter-day precision and accuracy of six analytes in plasma (n = 6).

Extraction recovery and matrix effect

A single-step LLE with dichloromethane proved to be simple, rapid and acceptable, with a mean extraction efficiency >85% at three QC concentration levels, indicating that the chosen LLE procedure was successful. The extraction recovery at three QC concentrations was 90.1–91.7% for apigenin, 88.9–92.5% for quercetin, 83.2–85.1% for apigenin-7-O-β-d-glucoside, 82.3–84.7% for quercetin-3-O-β-d-glucoside, 84.3–86.6% for 3′-methoxyluteolin-7-O-β-d-glucoside, and 85.2–87.1% for tricin-7-O-β-d-glucopyranoside, respectively (Table 4 ). The recovery of the IS was 93.0% in rat plasma (n  = 3).
Table 4

Recoveries, matrix effects and stability of six analytes in plasma (n = 3).

CompoundConcentration (ng/mL)Recovery
Matrix effect
Short-term stability
Long-term stability
Freeze–thaw stability
Average (%)RSD (%)Average (%)RSD (%)Remain (%)RSD (%)Remain (%)RSD (%)Remain (%)RSD (%)
Apigenin10.2690.16.296.113.096.26.697.67.1114.810.2
61.5690.88.198.65.792.63.288.29.598.45.7
461.791.712.5100.410.9101.82.8103.913.6106.14.7
Quercetin8.4288.910.7102.75.1105.311.297.15.7100.06.0
50.5292.58.2103.47.3112.05.298.23.9106.311.2
378.991.77.597.39.591.34.9109.55.894.110.1
Apigenin-7-O-β-d-glucoside7.6285.111.191.211.8102.20.8112.02.292.09.2
45.7283.25.090.49.195.67.990.611.091.33.7
342.985.07.288.37.691.110.2101.84.786.45.5
Quercetin-3-O-β-d-glucoside6.4084.710.086.712.587.410.494.43.8104.613.8
38.482.312.389.513.098.19.5107.714.2106.87.2
28882.79.790.210.4106.74.093.61.790.29.4
3′-Methoxyluteolin-7-O-β-d-glucoside10.2686.68.790.27.898.010.896.80.286.66.5
61.5684.512.194.35.398.36.788.13.589.82.0
461.784.313.893.15.8111.57.195.25.895.92.6
Tricin-7-O-β-d-glucopyranoside12.0487.14.896.59.192.62.5110.611.3108.98.3
72.2485.26.792.77.087.10.9100.21.9108.26.2
541.885.98.691.45.9107.30.8100.98.498.39.4
Recoveries, matrix effects and stability of six analytes in plasma (n = 3). The matrix effects of six analytes derived from QC samples were between 86.7% and 103.4%. Under these conditions, the analytes did not exhibit obvious matrix effect. The stability results showed that the concentrations of six analytes were between 86.4% and 114.8% of the initial values (Table 4), indicating that all the analytes were stable in rat plasma during the sample processing and storage stage.

Pharmacokinetics study

The validated LC–MS/MS method was successfully applied to the pharmacokinetic study and simultaneous determination of six flavonoids in rat plasma following intragastric administration of 183 mg extract per kg of body weight. The mean plasma concentration–time profiles of the six flavonoids are presented in Fig. 4 , and the main pharmacokinetic parameters calculated by non-compartmental analysis are listed in Table 5 . By using the method, we detected the drug concentration in plasma until 24 h after oral administration. The results in this study may be helpful for further investigations on the pharmacokinetics of P. tomentosa flowers, and beneficial for the application of this medicine in preclinical experiments.
Fig. 4

Plasma concentration–time curves of six analytes as a function of time following intragastric administrations (dose at 183 mg/kg) of P. tomentosa flower extract to rats (mean ± SD, n = 6).

Table 5

Pharmacokinetic parameters of the six flavonoids following oral administration of P. tomentosa flower extract (n = 6, mean ± SD).

ParametersPaulownia tomentosa
ApigeninQuercetinApigenin-7-O-β-d-glucosideQuercetin-3-O-β-d-glucoside3′-Methoxyluteolin-7-O-β-d-glucosideTricin-7-O-β-d-glucopyranoside
Cmax (ng/mL)141.4 ± 34.9314.8 ± 79.922.3 ± 4.044.3 ± 6.5122.6 ± 11.5129.0 ± 34.6
Tmax (h)7.6 ± 0.94.2 ± 1.12.8 ± 0.41.8 ± 0.83.8 ± 1.32.6 ± 0.5
AUC0–t (ng h/mL)1829.4 ± 364.02131.0 ± 417.597.5 ± 37.4186.3 ± 65.91002.2 ± 180.8743.7 ± 138.4
AUC0–∞ (ng h/mL)2352.8 ± 601.22857.3 ± 1262.0127.1 ± 32.7202.8 ± 66.41132.1 ± 281.11057.1 ± 135.4
MRT0–t (h)11.1 ± 0.57.8 ± 0.63.7 ± 1.13.5 ± 0.76.8 ± 0.69.6 ± 5.5
T1/2z (h)8.7 ± 3.68.4 ± 6.73.0 ± 1.62.7 ± 1.04.8 ± 0.95.9 ± 4.0
Plasma concentration–time curves of six analytes as a function of time following intragastric administrations (dose at 183 mg/kg) of P. tomentosa flower extract to rats (mean ± SD, n = 6). Pharmacokinetic parameters of the six flavonoids following oral administration of P. tomentosa flower extract (n = 6, mean ± SD).

Conclusions

A selective, sensitive and robust LC–MS/MS method for simultaneous determination of six flavonoids in rat plasma was established. The method employed a simple and rapid extraction procedure for sample preparation, and offered higher sensitivity with little detectable coeluting endogenous substances requiring only 50 μL plasma. This method is proposed for the pharmacokinetic study and preclinical monitoring of P. tomentosa.
  11 in total

1.  Bioanalytical method validation--a revisit with a decade of progress.

Authors:  V P Shah; K K Midha; J W Findlay; H M Hill; J D Hulse; I J McGilveray; G McKay; K J Miller; R N Patnaik; M L Powell; A Tonelli; C T Viswanathan; A Yacobi
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Geranylated flavanones from the secretion on the surface of the immature fruits of Paulownia tomentosa.

Authors:  Teigo Asai; Noriyuki Hara; Sawa Kobayashi; Shiro Kohshima; Yoshinori Fujimoto
Journal:  Phytochemistry       Date:  2008-03       Impact factor: 4.072

3.  Cholinestrase inhibitory effects of geranylated flavonoids from Paulownia tomentosa fruits.

Authors:  Jung Keun Cho; Young Bae Ryu; Marcus J Curtis-Long; Hyung Won Ryu; Heung Joo Yuk; Dae Wook Kim; Hye Jin Kim; Woo Song Lee; Ki Hun Park
Journal:  Bioorg Med Chem       Date:  2012-03-08       Impact factor: 3.641

4.  Neuroprotective effects of a sesquiterpene lactone and flavanones from Paulownia tomentosa Steud. against glutamate-induced neurotoxicity in primary cultured rat cortical cells.

Authors:  Soo-Ki Kim; Sang-Buem Cho; Hyung-In Moon
Journal:  Phytother Res       Date:  2010-12       Impact factor: 5.878

5.  Tomentomimulol and mimulone B: two new C-geranylated flavonoids from Paulownia tomentosa fruits.

Authors:  K Schneiderová; T Slapetová; R Hrabal; H Dvořáková; P Procházková; J Novotná; M Urbanová; J Cvačka; K Smejkal
Journal:  Nat Prod Res       Date:  2012-05-01       Impact factor: 2.861

6.  Cytotoxic activities of several geranyl-substituted flavanones.

Authors:  Karel Smejkal; Jana Svacinová; Tereza Slapetová; Kristýna Schneiderová; Stefano Dall'acqua; Gabbriella Innocenti; Veronika Závalová; Peter Kollár; Stanislav Chudík; Radek Marek; Ondrej Julínek; Marie Urbanová; Murat Kartal; Marek Csöllei; Karel Dolezal
Journal:  J Nat Prod       Date:  2010-04-23       Impact factor: 4.050

7.  Minor C-geranylated flavanones from Paulownia tomentosa fruits with MRSA antibacterial activity.

Authors:  Alice Navrátilová; Kristýna Schneiderová; Daniela Veselá; Zuzana Hanáková; Anna Fontana; Stefano Dall'Acqua; Josef Cvačka; Gabbriella Innocenti; Jana Novotná; Marie Urbanová; Jerry Pelletier; Alois Čížek; Helena Žemličková; Karel Šmejkal
Journal:  Phytochemistry       Date:  2013-03-01       Impact factor: 4.072

8.  [Flavones from flowers of Paulownia fortunei].

Authors:  Pei-fen Zhang; Chong Li
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  2008-11

9.  Antibacterial C-geranylflavonoids from Paulownia tomentosa Fruits.

Authors:  Karel Smejkal; Stanislav Chudík; Pavel Kloucek; Radek Marek; Josef Cvacka; Marie Urbanová; Ondrej Julínek; Ladislav Kokoska; Tereza Slapetová; Pavla Holubová; Ales Zima; Margita Dvorská
Journal:  J Nat Prod       Date:  2008-02-23       Impact factor: 4.050

10.  Antiradical and cytoprotective activities of several C-geranyl-substituted flavanones from Paulownia tomentosa fruit.

Authors:  Ales Zima; Jan Hosek; Jakub Treml; Jan Muselík; Pavel Suchý; Gabriela Prazanová; Ana Lopes; Milan Zemlicka
Journal:  Molecules       Date:  2010-08-31       Impact factor: 4.411

View more
  2 in total

1.  Extraction, Purification, and Hydrolysis Behavior of Apigenin-7-O-Glucoside from Chrysanthemum Morifolium Tea.

Authors:  Yuxiao Wang; Zhenzhen Xu; Yuqi Huang; Xin Wen; Yue Wu; Yuhan Zhao; Yuanying Ni
Journal:  Molecules       Date:  2018-11-09       Impact factor: 4.411

2.  Comparative Phytochemical, Antioxidant, and Hemostatic Studies of Extract and Four Fractions from Paulownia Clone in Vitro 112 Leaves in Human Plasma.

Authors:  Weronika Adach; Jerzy Żuchowski; Barbara Moniuszko-Szajwaj; Malgorzata Szumacher-Strabel; Anna Stochmal; Beata Olas; Adam Cieslak
Journal:  Molecules       Date:  2020-09-23       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.